One Year Follow-Up Study of T-Cell Subsets and Incidence of Seropositivity for HTLV-I and HTLV-III Antibodies in Patients Treated “On Demand” or Sporadically with Clotting Concentrates

Rodeghiero, Francesco; Castaman, Giancarlo; Chisesi, Teodoro; Rossi, Anita De; Gassa, O. Dalla; Mistro, Annarosa Del; Dini, E; Castronovo, S; Pornaro, E.; Chieco‐Bianchi, Luigi

doi:10.1055/s-0038-1660093

Cited by 3 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar abnormalities were detected in the seropositive recipients ' of commercial concentrates. Our findings are in agreement with those of Gjerset et al (11).They are, however, in conflict with ealier reports of other authors (7,8,15,16) who described normal T-cell subset ratios in cryoprecipitate treated groups. The discrepancy in the results may be explained by differences in total lifetime doses of cryoprecipitate.…”

Section: Discussionsupporting

confidence: 82%

HIV Antibody Status and Immunological Abnormalities in Polish Haemophiliacs

Łopaciuk¹,

Kacperska²,

Głoskowska-Moraczewska³

et al. 1987

Thromb Haemost

View full text Add to dashboard Cite

SummarySera of 520 multitransfused haemophiliacs were examined for antibody to HIV; 447 patients had haemophilia A and 73 had haemophilia B. In 382 patients with haemophilia A and in 62 with haemophilia B solely Polish-made blood products were used for replacement therapy. The remaining haemophiliacs had also received imported clotting factor concentrates prior to the investigation. Only 8 patients (haemophilia A - 7, haemophilia B - 1) developed anti-HIV and all of them had been exposed to commercial concentrates. The analysis of T-cell subsets demonstrated an inverted T4/T8 ratio (less than 1.0) in 7 (30%) of the 23 haemophiliacs treated solely with domestic cryoprecipitate and in 3 (37%) of the 8 seropositive recipients of commercial concentrates. The most frequent alteration in both subgroups was a reduced ratio with either normal absolute numbers or an increase in T8 cells. Increased serum IgG levels were found in 82% of the users of cryoprecipitate and in 75% of the seropositive patients. Serum beta-2-microglobulin level was elevated in 69 and 62% of each subgroup, respectively. The observed immunological abnormalities, at least in the cryoprecipitate treated subgroup, may be causally related to factors other than HIV infection.

show abstract

Section: Discussionsupporting

confidence: 82%

HIV Antibody Status and Immunological Abnormalities in Polish Haemophiliacs

Łopaciuk¹,

Kacperska²,

Głoskowska-Moraczewska³

et al. 1987

Thromb Haemost

View full text Add to dashboard Cite

show abstract

“…The vasopressin analogue 1 -desamino-8-Darginine vasopressin (desmopressin, DDAVP) temporarily corrects the underlying haemostatic defect in some patients with von Willebrand's disease (vWd) or haemophilia A by eliciting the release into the bloodstream of endogenous procoagulant factor VIII (V1II:C) and von Willebrand factor (vWf) (1). Whenever possible, this agent should be preferred in the treatment or prevention of haemorrhages, since it avoids the risk of blood derivatives transmitting bloodborne viruses, of inducing immunological abnormalities and of causing allergic reactions (2)(3)(4).…”

mentioning

confidence: 99%

Hyper‐responsiveness to DDAVP for patients with type I von Willebrand's disease and normal intra‐platelet von Willebrand factor

Rodeghiero

Castaman

Bona

et al. 1988

European J of Haematology

View full text Add to dashboard Cite

Desmopressin (DDAVP) has gained wide acceptance as the drug of first choice in the treatment or prevention of haemorrhages in the majority of patients with von Willebrand's disease (vWd). However, data concerning the clinical effectiveness of DDAVP refer generally to mild vWd, with factor VIII and VW factor levels usually above 20% of normal. In 14 patients with type I vWd characterized by very low plasma levels of factor VIII coagulant activity (VII1:C) and vWf, measured as ristocetin cofactor activity (lower than 20% and 3% of normal respectively), but with a normal intraplatelet content of vWf, a test infusion of DDAVP (0.4 pg/kg) elicited a very marked increase of VII1:C and vWf and normalized the bleeding time. All these patients subsequently underwent tooth extraction after DDAVP infusion. The incidence of bleeding was remarkably low, with only two minor late bleeding episodes easily stopped by repeating DDAVP infusion. Compared to the cases of type 1 vWd with unknown intrapletelet vWf content reported in the literature, this subgroup of patients had a more marked, albeit short-lived, increment of VII1:C and vWf.

show abstract

Human immunodeficiency virus infection in hemophiliac patients

Daul

deShazo

1988

The American Journal of Medicine

View full text Add to dashboard Cite

One Year Follow-Up Study of T-Cell Subsets and Incidence of Seropositivity for HTLV-I and HTLV-III Antibodies in Patients Treated “On Demand” or Sporadically with Clotting Concentrates

Cited by 3 publications

References 18 publications

HIV Antibody Status and Immunological Abnormalities in Polish Haemophiliacs

HIV Antibody Status and Immunological Abnormalities in Polish Haemophiliacs

Hyper‐responsiveness to DDAVP for patients with type I von Willebrand's disease and normal intra‐platelet von Willebrand factor

Human immunodeficiency virus infection in hemophiliac patients

Contact Info

Product

Resources

About